Loading...

We've got a brand new version of Simply Wall St! Try it out

Exopharm

ASX:EX1
Snowflake Description

Flawless balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
EX1
ASX
A$35M
Market Cap
  1. Home
  2. AU
  3. Pharmaceuticals & Biotech
Company description

Exopharm Limited, a biopharmaceutical company, focuses on developing and commercializing human therapeutics in Australia. The last earnings update was 80 days ago. More info.


Add to Portfolio Compare Print
  • Exopharm has significant price volatility in the past 3 months.
EX1 Share Price and Events
7 Day Returns
-1.3%
ASX:EX1
4.7%
AU Biotechs
0.9%
AU Market
1 Year Returns
-
ASX:EX1
50.9%
AU Biotechs
16.3%
AU Market
EX1 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Exopharm (EX1) -1.3% -7.4% 2.7% - - -
AU Biotechs 4.7% 8.7% 20% 50.9% 168.8% 226.4%
AU Market 0.9% 1.9% 5.1% 16.3% 22.3% 22.5%
1 Year Return vs Industry and Market
  • No trading data on EX1.
  • No trading data on EX1.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is Exopharm undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Exopharm. This is due to cash flow or dividend data being unavailable. The share price is A$0.375.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Exopharm's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Exopharm's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:EX1 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in AUD A$-0.04
ASX:EX1 Share Price ** ASX (2019-11-17) in AUD A$0.38
Global Biotechs Industry PE Ratio Median Figure of 145 Publicly-Listed Biotechs Companies 30.8x
Australia Market PE Ratio Median Figure of 519 Publicly-Listed Companies 18.63x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Exopharm.

ASX:EX1 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:EX1 Share Price ÷ EPS (both in AUD)

= 0.38 ÷ -0.04

-9.32x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Exopharm is loss making, we can't compare its value to the Global Biotechs industry average.
  • Exopharm is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does Exopharm's expected growth come at a high price?
Raw Data
ASX:EX1 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -9.32x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Global Biotechs Industry PEG Ratio Median Figure of 85 Publicly-Listed Biotechs Companies 1.39x
Australia Market PEG Ratio Median Figure of 347 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Exopharm, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Exopharm's assets?
Raw Data
ASX:EX1 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in AUD A$0.06
ASX:EX1 Share Price * ASX (2019-11-17) in AUD A$0.38
Australia Biotechs Industry PB Ratio Median Figure of 38 Publicly-Listed Biotechs Companies 3.17x
Australia Market PB Ratio Median Figure of 1,584 Publicly-Listed Companies 1.75x
ASX:EX1 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:EX1 Share Price ÷ Book Value per Share (both in AUD)

= 0.38 ÷ 0.06

5.9x

* Primary Listing of Exopharm.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Exopharm is overvalued based on assets compared to the AU Biotechs industry average.
X
Value checks
We assess Exopharm's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Exopharm has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Exopharm expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Exopharm has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Exopharm expected to grow at an attractive rate?
  • Unable to compare Exopharm's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Exopharm's earnings growth to the Australia market average as no estimate data is available.
  • Unable to compare Exopharm's revenue growth to the Australia market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
ASX:EX1 Future Growth Rates Data Sources
Data Point Source Value (per year)
Australia Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 13%
Australia Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 10.3%
Australia Market Earnings Growth Rate Market Cap Weighted Average 9.7%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:EX1 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:EX1 Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2019-06-30 -2 -2
2018-06-30 0 0 0
2017-06-30 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Exopharm is high growth as no earnings estimate data is available.
  • Unable to determine if Exopharm is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:EX1 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Exopharm Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:EX1 Past Financials Data
Date (Data in AUD Millions) EPS *
2019-06-30 -0.04
2018-06-30 -0.01
2017-06-30 -0.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Exopharm will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Exopharm's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Exopharm's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Exopharm's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Exopharm's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Exopharm has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Exopharm performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Exopharm's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Exopharm does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Exopharm's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Exopharm's 1-year growth to the Global Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Exopharm's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Exopharm Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:EX1 Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 -2.28 1.36
2018-06-30 0.04 -0.17 0.12
2017-06-30 0.00 0.00
2016-06-30 0.00 0.00
2015-06-30 0.00 0.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Exopharm has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Exopharm has efficiently used its assets last year compared to the Global Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Exopharm improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Exopharm's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Exopharm has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Exopharm's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Exopharm's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Exopharm is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Exopharm has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Exopharm's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Exopharm has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Exopharm Company Filings, last reported 4 months ago.

ASX:EX1 Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 5.12 0.00 4.42
2018-06-30 -0.01 0.00 0.05
2017-06-30 0.00 0.00
2016-06-30 0.00 0.00
2015-06-30 0.00 0.00
  • Exopharm has no debt.
  • Exopharm currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Exopharm has sufficient cash runway for 1.5 years based on current free cash flow.
  • Exopharm has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 117.1% each year.
X
Financial health checks
We assess Exopharm's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Exopharm has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Exopharm's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Exopharm dividends.
If you bought A$2,000 of Exopharm shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Exopharm's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Exopharm's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:EX1 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 59 Stocks 2.1%
Australia Market Average Dividend Yield Market Cap Weighted Average of 390 Stocks 4%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.5%
Australia Bottom 25% Dividend Yield 25th Percentile 2.4%
Australia Top 25% Dividend Yield 75th Percentile 5.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Exopharm has not reported any payouts.
  • Unable to verify if Exopharm's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Exopharm's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Exopharm has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Exopharm's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Exopharm afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Exopharm has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Exopharm's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Ian Dixon
CEO Bio

Dr. Ian E. Dixon, PhD, MBA, MAICD, has been an Executive Director at Medigard Limited since November 2017 and has been its Chairman of Scientific and Medical Advisory Panel since December 2017. Dr. Dixon serves as Company Founder, Technology Co-Founder, Managing Director and a Director of Exopharm Limited. Dr. Dixon serves as the Chief Executive Officer and Executive Director of Genscreen Pty Ltd. Dr. Dixon has worked in Australia, Cambridge (UK) and the USA, with extensive business dealings in Asia, Japan and China. He is the founder/co-founder of Okedro Pty Ltd. In 2011, he co-founded Cynata Inc. He co-founded Genscreen Pty Ltd in 2002. From 1987 to 1995, he grew two successful export-oriented manufacturing and R&D businesses - both purchased by public companies. Dr. Dixon ha a track record of building value in innovative medical-relate products and technologies. In 1995, he joined Vision Systems as the Director of the Product Group within the Invetech business unit and managed the team responsible for developing innovative diagnostic, pathology automation and security system products. He is an experienced business-builder and has over 23 years of international experience in the formation and growth of successful businesses and partnerships. He is a Member of a range of International biomedical societies, including the International Society for Cellular Therapy, the International Society for Biological Therapy of Cancer, the International Liposome Society, the International Society for Antiviral Research, the International Society for Stem Cell Research and the International Society for Influenza and other Respiratory Virus Diseases. Dr. Dixon served as the Chairman of Scientific Advisory Board of Cynata Therapeutics Limited (Formerly Eco Quest Limited). He has been an Independent Non-Executive Director of Noxopharm Limited since March 15, 2016. He served as a Director of Cynata Incorporated. He served as a Non-executive Director of Cell Therapies Pty Ltd. He also belongs to the American Australian Association, the Australian Institute of Company Directors, University House (University of Melbourne), Finsia (previously Securities Institute of Australia) and Royal Automotive Club of Victoria. He qualified as a mechanical engineer in the early 1980s and then also completed a course in Electronics Engineering. Dr. Dixon holds a PhD in Biomedical Engineering and Bachelor of Engineering from Monash University and an MBA and professional engineering qualifications from Swinburne University.

CEO Compensation
  • Insufficient data for Ian to compare compensation growth.
  • Insufficient data for Ian to establish whether their remuneration is reasonable compared to companies of similar size in Australia.
Management Team

Ian Dixon

TITLE
Company Founder

Gregory Lichtfuss

TITLE
COO & Technology Co-Founder

Chris Baldwin

TITLE
Chief Commercial Officer
TENURE
0.1 yrs

David Parker

TITLE
Company Secretary & Non-Executive Director
AGE
40
Board of Directors

Jason Watson

TITLE
Non-Executive Chairman

Ian Dixon

TITLE
Company Founder

David Parker

TITLE
Company Secretary & Non-Executive Director
AGE
40
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Exopharm individual insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
15. Sep 19 Buy Jason Watson Individual 13. Sep 19 13. Sep 19 100,000 A$0.37 A$37,000
X
Management checks
We assess Exopharm's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Exopharm has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

What Type Of Shareholder Owns Exopharm Limited's (ASX:EX1)?

So it's nice to see some insider ownership, because it may suggest that management is owner-oriented. … Exopharm is a smaller company with a market capitalization of AU$36m, so it may still be flying under the radar of many institutional investors. … institutional investors have not yet purchased much of the company.

Simply Wall St -

Company Info

Description

Exopharm Limited, a biopharmaceutical company, focuses on developing and commercializing human therapeutics in Australia. The company is Plexaris and Exomere products, including non-clinical, pre-clinical, and clinical testing for other medical conditions, such as dry age-related macular degeneration and osteoarthritis. Exopharm Limited was founded in 2013 and is headquartered in Melbourne, Australia.

Details
Name: Exopharm Limited
EX1
Exchange: ASX
Founded: 2013
A$35,324,640
95,472,000
Website: http://www.exopharm.com
Address: Exopharm Limited
31 Queen Street,
Level 17,
Melbourne,
Victoria, 3000,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX EX1 Ordinary Shares Australian Securities Exchange AU AUD 18. Dec 2018
CHIA EX1 Ordinary Shares Chi-X Australia AU AUD 18. Dec 2018
Number of employees
Current staff
Staff numbers
18
Exopharm employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/18 10:47
End of day share price update: 2019/11/17 00:00
Last earnings filing: 2019/08/30
Last earnings reported: 2019/06/30
Last annual earnings reported: 2019/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.